Lanean...
mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia
We have previously demonstrated that mTOR inhibitors (MTIs) are active in preclinical models of acute lymphoblastic leukemia (ALL). MTIs may increase degradation of cyclin D1, a protein involved in dihydrofolate reductase (DHFR) synthesis. Because resistance to methotrexate may correlate with high D...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Society of Hematology
2008
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2518903/ https://ncbi.nlm.nih.gov/pubmed/18544682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-137141 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|